Table 2.
logistic analysis of the association between slamf9 expression and clinical characteristics.
Characteristics | Total (N) | OR (95% CI) | P value |
---|---|---|---|
Pathologic T stage (T3&T4 vs. T1&T2) | 641 | 1.898 (1.279–2.815) | 0.001 |
Pathologic N stage (N2&N1 vs. N0) | 640 | 1.486 (1.084–2.036) | 0.014 |
Pathologic M stage (M1 vs. M0) | 564 | 1.262 (0.801–1.988) | 0.316 |
Pathologic stage (Stage III & Stage IV vs. Stage I & Stage II) | 623 | 1.477 (1.074–2.029) | 0.016 |
Gender (Male vs. Female) | 644 | 1.119 (0.821–1.525) | 0.477 |
Age (> 65 vs. <= 65) | 644 | 1.079 (0.790–1.474) | 0.633 |
CEA level (> 5 vs. <= 5) | 415 | 1.361 (0.912–2.030) | 0.131 |
P < 0.05, and the results were statistically significant.